FDA's Peter Marks backs accelerated approval for gene therapies

An FDA official kicked off the 2023 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference Monday with a keynote address that described the steps the agency is taking to advance the development of gene therapies for rare disorders.

Peter Marks, director of the FDA's Center for Biologics Evaluation and Research (CBER), summarized his speech in an interview with Neurology Live, in which he highlighted the work of the MDA, in particular.